For every cell, there is a time to live and a time to die. It is apparent that cell life and death decisions are taken by individual cells based on their interpretation of physiological or non-physiological stimuli, or their own self-assessment of internal damage or changes in their environment. Apoptosis or programmed cell death is a key regulator of physiological growth control and regulation of tissue homoeostasis. One of the most important advances in cancer research in recent years is the recognition that cell death, mostly by apoptosis, is crucially involved in the regulation of tumour formation and also critically determines treatment response. The initiation and progression of cancer, traditionally seen as a genetic disease, is now realized to involve epigenetic abnormalities along with genetic alterations. The study of epigenetic mechanisms in cancer, such as DNA methylation, histone modifi cations and microRNA expression, has revealed a plethora of events that contribute to the neoplastic phenotype through stable changes in the expression of genes critical to cell death pathways. A better understanding of the epigenetic molecular events that regulate apoptosis, together with the reversible nature of epigenetic 1 To whom correspondence should be addressed (email n.hajji@imperial.ac.uk).
Introduction
Cell life and death decisions are taken by individual cells based on their interpretation of physiological or non-physiological stimuli, or their own self-assessment of internal damage or changes in their environment. Cells that represent a threat to the organism integrity, such as damaged, infected or aged cells, are eliminated by a process called PCD (programmed cell death). Thus PCD is a biological phenomenon which is of fundamental importance to the integrity of organisms.
PCD
Apoptosis or PCD is a key regulator of physiological growth control and regulation of tissue homoeostasis. One of the most important advances in cancer research in recent years is the recognition that cell death, mostly by apoptosis, is crucially involved in the regulation of tumour formation and also critically determines treatment response. Killing of tumour cells by most anticancer strategies currently used in clinical oncology, for example, chemotherapy, γ-irradiation, suicide gene therapy or immunotherapy, has been linked to activation of apoptosis signal-transduction pathways in cancer cells, such as the intrinsic and/or extrinsic pathway. Thus failure to undergo apoptosis may result in treatment resistance [1] . Understanding the molecular events that regulate apoptosis in response to anticancer chemotherapy, and how cancer cells evade apoptotic death, provides novel opportunities for a more rational approach to develop molecular-targeted therapies for combating cancer.
The intrinsic pathway
The intrinsic pathway is initiated from within the cell. This is usually in response to cellular signals resulting from DNA damage, a defective cell cycle, detachment from the extracellular matrix, hypoxia, loss of cell survival factors or other types of severe cell stress. The intrinsic pathway, also known as the mitochondrial pathway, is activated by stimuli that lead to MOMP (mitochondrial outer membrane permeabilization) and the release of pro-apoptotic proteins from the mitochondrial IMS (intermembrane space) [2] . Among these factors, there are several proteins that initiate or regulate caspase activation, including cytochrome c. In the cytosol, cytochrome c binds the adaptor Apaf-1 (apoptotic protease-activating factor 1), and in the presence of dATP it forms a large multiprotein structure known as the apoptosome [3] . The apoptosome creates a platform that brings together molecules of the initiator caspase of the intrinsic pathway caspase 9 enabling their autoactivation, which in turn activates the downstream effector caspases 3, 6 abrogate pro-apoptotic receptor stimulation [12] . It has been shown that activation of the extrinsic pathway can result in two apoptotic programmes, termed type I and type II. In type I cells, adequate amounts of active caspase 8 are generated at the DISC to directly activate the effector caspases and execute cell death [13] . Conversely, in the case of type II cells, which produce minimal amounts of active caspase 8 at the DISC, an intermediate amplifi cation of the signal involves the BH3-only Bcl2 family protein Bid. The cleavage of Bid by caspase 8 results in its translocation to the mitochondria where it activates pro-apoptotic proteins Bax and Bak and initiates the release of mitochondrial factors, which in turn augment cell death.
Although apoptosis pathways and signal-transducing molecules have been shown to play a crucial role in the killing of tumour cells in response to cytotoxic agents used in the treatment of cancer patients, the signifi cance of apoptosis as the main mechanism of cancer cell death in response to anticancer chemotherapy has also been challenged. In addition to apoptosis, cancer cells have also been shown to be effectively eliminated after DNA damage by necrosis, mitotic catastrophe and autophagic cell death [14] .
Epigenetics and PCD
Classical genetics alone cannot explain the diversity of phenotypes within a population. Nor does classical genetics explain how, despite their identical DNA sequences, monozygotic twins [15] or cloned animals [16] can have different phenotypes and different susceptibilities to a disease. The concept of epigenetics offers a partial explanation of these phenomena. First introduced by C.H. Waddington in 1939 to name "the causal interactions between genes and their products, which bring the phenotype into being" [17] , epigenetics was later defi ned as heritable changes in gene expression that are not due to any alteration in the DNA sequence [18] . Epigenetic mechanisms are essential for normal development and maintenance of tissue-specifi c gene expression patterns in mammals. Disruption of epigenetic processes can lead to altered gene function and malignant cellular transformation. Global changes in the epigenetic landscape are a hallmark of cancer. The initiation and progression of cancer, traditionally seen as a genetic disease, is now realized to involve epigenetic abnormalities along with genetic alterations. The study of epigenetic mechanisms in cancer, such as DNA methylation, histone modifications, nucleosome positioning and miRNA (microRNA) expression, has revealed a plethora of events that contribute to the neoplastic phenotype through stable changes in the expression of genes critical to cell-death pathways.
DNA methylation
Mechanism of action DNA methylation is a covalent modification formed by the addition of a methyl group at the 5´ carbon of cytosine in the sequence context CpG dinucleotides of the DNA molecule. The reaction is catalysed by a family of enzymes called DNMTs (DNA methyltransferases) which catalyse the transfer of a methyl group from the methyl donor SAM (S-adenosyl-L-methionine). Three active DNMTs, DNMT1, DNMT3A and DNMT3B, have been identified in mammals. A fourth enzyme previously known as DNMT2 is not a DNMT but is a protein that is closely related to DNMT3A and DNMT3B structurally and that is critical for DNA methylation, but appears to be inactive on its own. The modifi cation is generally repressive to transcription and helps to maintain silencing of transposable elements, therefore enhancing genome stability. A number of transcription factors recognize sequences that contain CpG residues [e.g. AP-2, c-Myc/Myn, the CREB (cAMP-response-element-binding protein), E2F and NF-κB (nuclear factor κB)], and their binding has been shown to be inhibited by methylation. DNA methylation attracts specifi c MBDs (methyl-DNA binding proteins) (MeCP2, MBD1, MBD2, MBD3, MBD4 and KAISO) which seem to act as a molecular switch to turn off the expression of genes. Most CpG sequences in the genome are methylated. However, there are 'CpG islands' associated with gene promoters that escape DNA methylation.
DNA methylation and cancer
A link between DNA methylation and cancer was fi rst demonstrated in 1983, when it was shown that the genomes of cancer cells are hypomethylated relative to their normal counterparts [19] . Hypomethylation in tumour cells is primarily due to the loss of methylation from repetitive regions of the genome. Global demethylation early in tumorigenesis might predispose cells to genomic instability and further genetic changes. Aberrant hypermethylation in cancer usually occurs at CpG islands, and the resulting changes in chromatin structure effectively silence transcription. Cancer cells usually acquire aberrant methylation of multiple tumour-related genes that co-operate to confer survival advantage on neoplastic cells [20] . Therefore DNA-methylationmediated down-regulation of genes involved in cell death could be a signifi cant mechanism through which tumour cells avoid cell death.
DNA methylation and apoptosis
Evidence gained from studies in different cancers have shown that alteration of pro-and anti-apoptotic genes by DNA methylation affects all aspect of apoptosis right from its initiation to its execution (Table 1) . DNA methylation has been shown to contribute to inactivation of both the intrinsic and the extrinsic apoptotic pathways (Figure 1 ). DNA hypermethylation is one mechanism that contributes to the down-regulation of Fas expression which could afford cells protection from FasL-induced apoptosis and thereby aid the emergence of a tumorigenic clone during progression from normal colonic epithelium to adenocarcinoma [21] . DR4 and DR5 are the receptors for TRAIL and binding of TRAIL to the cognate receptors induces caspase-dependent apoptosis. In addition, two decoy receptors for TRAIL Promoter hypermethylation KAS-6/1 multiple myeloma cell line [120] Possible alteration on H3 and
H4 acetylation
Tumorigenesis in Apc− mice [121] Low expression of miR-34a
Chronic lymphocytic leukaemia [122] BaK Bcl-2 homologous antagonist/killer
Promoter hypermethylation KAS-6/1 multiple myeloma cell line [120] PUMA p53 up-regulated modulator or apoptosis Promoter hypermethylation KAS-6/1 multiple myeloma cell line [120] Up-regulated miRNA-221-222
Glioma cells [123] BIM Bcl-2-interacting mediator of cell death
Promoter hypermethylation
Chronic myeloid leukaemia [31] Histone modifi cation (H3K27-Me3)
Burkitt's lymphoma [124] p53 Tumour protein 53
Suppressed miRNA miR-34
Human gastric cancer [125] Promoter hypermethylation Acute lymphatic leukaemia patients [126] have been described, DcR1 (decoy receptor 1) and DcR2. DcR1 and DcR2, which also bind TRAIL, compete with DR4 and DR5 for the ligand, but do not induce apoptosis. DR4, DR5 and more frequently DcR1 and DcR2 have been shown to be down-regulated by methylation in tumours [22] [23] [24] . DR4 promoter methylation is frequent in human astrocytic gliomas and phaeochromocytoma, and epigenetic silencing of DR4 mediates resistance to TRAIL/DR4-based therapies [25] . Engagement of these transmembrane death receptors by their respective ligand promote the formation of the DISC complex and the activation of caspase 8 within. Inactivation of caspase 8 (and caspase 10) by DNA methylation has been reported in numerous cancer types including small cell lung carcinoma, glioblastoma and paediatric tumours (i.e. rhabdomyosarcoma, medulloblastoma, retinoblastoma and neuroblastoma). DAPK (death-associated protein kinase) is a Ca 2+ /calmodulin-regulated, serine/threonine microfilament-bound kinase shown to be key player in multiple cell death signalling pathways [26, 27] . DAPK also acts as a tumour suppressor, as its gene silencing via promotor methylation is implicated in tumorigenesis [28] . DAPK contributes to the extrinsic apoptotic pathway and hypermethylation of the DAPK promoter attenuates the sensitivity to IFN-γ (interferon γ)-, TNF-α-, FasL-and TRAIL-induced apoptosis in cancer cells. The p53 protein is a key player in the regulation of cell life and death decisions. When a cell suffers DNA damage or another cellular stress, its p53 proteins are activated and send a death signal to the cell. The contribution of DNA methylation to p53 gene expression is more complex. p53 is the most frequently altered gene in human cancer, with approx. 50% of all types of cancers carrying a mutation in p53, usually accompanied by LOH (loss of heterozygosity) [29] . Unlike the majority of tumour suppressor genes that are mutated in human tumours, the wild-type allele of p53 is seldom transcriptionally silenced through methylation, but is lost from the genome through deletions of various degrees on chromosome 17 [30] . It is to be noted that even uncommon p53 gene silencing by DNA hypermethylation has been reported in a group of acute lymphatic leukaemia patients [31, 32] . p53 activates the expression of HIC1 (hypermethylated in cancer 1), which in turn directly regulates SIRT1 (sirtuin 1) to modulate p53-dependent DNA-damage responses [33, 34] . As its name indicates, HIC1 expression is found in various cancers to be silenced by DNA hypermethylation. The loss of HIC1 results in up-regulated SIRT1 expression in cancer cells; this deacetylates and inactivates p53, allowing cells to bypass apoptosis and survive DNA damage.
The BH3-only protein Bim directly binds to Bax, causes its activation and participates in the intracellular signal transduction pathway of cell death. Down-regulation of BIM expression by promoter hypermethylation contributes to renal cell carcinoma and chronic myeloid leukaemia apoptosis resistance [31, 35] .
Downstream of the mitochondria, several other key apoptotic players have also been seen to be modulated by DNA methylation mechanisms. Inactivation of the Apaf-1 (apoptotic protease-activating factor 1) gene is implicated in disease progression and chemoresistance of some malignancies. Apaf-1 DNA methylation was observed at high frequencies in multiple types of leukaemia, melanoma, gastric, bladder and kidney cancer [36] [37] [38] [39] [40] . XAF1 [XIAP (X-linked inhibitor of apoptosis)-associated factor 1] belongs to a family of proteins that inhibit IAPs (inhibitors of apoptosis). XAF1 negatively regulates XIAP, which are potent inhibitors of caspase 3, 7 and 9 and sensitize cells to cell death triggers. Aberrant hypermethylation of the CpG sites in the XAF1 promoter is strongly associated with lower expression of XAF1 in gastric cancers [41, 42] .
Histone covalent modifi cation
Histone-modifying enzymes manage post-translational modifi cations of histones In addition to DNA methylation, modifi cations of histones are important determinants of the epigenetic state. In eukaryotes, an octamer of histones H2A, H2B, H3 and H4 is wrapped by 147 bp of DNA to form a nucleosome, the fundamental unit of chromatin. Histones are the chief protein components of chromatin, act as spools around which DNA winds and play a role in gene regulation [43] . Histones are subject to a wide variety of post-translational modifications including, but not limited to, lysine acetylation, lysine and arginine methylation, serine and threonine phosphorylation, and lysine ubiquitination and SUMOylation, as well as ADP-ribosylation and carbonylation [44] . These modifi cations occur primarily within the histone N-terminal tails protruding from the surface of the nucleosome as well as on the globular core region [45] . The histone-modifying enzymes affect histones either locally, through targeted recruitment by sequence-specific transcription factors [46] , or globally throughout the genome in an untargeted manner affecting virtually all nucleosomes [47] . The best characterized histone modifi cations are acetylation, and methylation. In 'normal' cells, genomic regions that include the promoters of tumour-suppressor genes are enriched in histone-modification marks associated with active transcription, such as acetylation of H3 and H4 lysine (K) residues (for instance H3K9ac, H4K5ac, H4K8ac, H4K12 and H4K16ac) and trimethylation of K4 of H3 (H3K4me3) [48] . In the same cells, DNA repeats and other heterochromatic regions are generally deacetylated, but characterized by trimethylation of Lys 27 and tri-and di-methylation of Lys 9 of H3 (H3K27me3, H3K9me2 and H3K9me3), and trimethylation of Lys 20 of H4 (H4K20me3), which function as repressive marks [49, 50] . However, there are no absolute rules and many active and inactive genes have overlapping patterns of histone modifi cations. Nevertheless, it is clear that aberrant regulation of histone modification can affect gene activity and therefore oncogenic potential exists. Histone modifi cations are proposed to affect chromosome function through at least two distinct mechanisms. The fi rst mechanism suggests that modifi cations may alter the electrostatic charge of the histone, resulting in a structural change in histones or their binding to DNA. The second mechanism proposes that these modifi cations are binding sites for protein recognition modules, such as the bromodomains or chromodomains, which recognize acetylated lysines or methylated lysine residues respectively.
Histone-modifying enzymes
For each modifi cation, enzymes exist which either lay down the appropriate mark or remove it. Major players in this regulation are the HATs (histone acetyltransferases), which acetylate the histone tails and induce chromatin decondensation, HDACs (histone deacetylases), which remove the acetyl groups and promote a tighter binding of histones to DNA, HMTs (histone methyltransferases), which promote or inhibit transcription depending on the target histone residue, and HDMs (histone demethylases) which counteract the HMTs. HATs generally contain multiple subunits, and the functions of the catalytic subunit depend largely on the context of the other subunits in those complexes. HATs are grouped into different family classes based on their catalytic domains. Gcn5 is the founding member of the GNAT (Gcn5 N-acetyltransferase) family, that includes Gcn5, PCAF, Elp3, Hat1a, Hpa2 and Nut1a. The MYST HATs are named for the founding members of this family: Esa1, Mof, Moz, Morf, Ybf2/Sas3, Sas2, Hbo1 and Tip60. Although these two families of HATs are the predominant ones, other proteins including p300/CBP (CREB-binding protein), TAFII250 and a number of nuclear receptor co-activators, have also been shown to possess intrinsic HAT activity.
HDAC proteins occur in four groups depending on their sequence similarity and cofactor dependency. The fi rst two groups are considered 'classical' HDACs whose activities are inhibited by TSA (trichostatin A), whereas the third group is a family of NAD + -dependent proteins not affected by TSA. The fourth group is considered an atypical category of its own, based solely on DNA sequence similarity to the others. Homologues to the fi rst three groups are found in yeast having the names: Rpd3 (reduced potassium dependency 3), which corresponds to Class I; hda1 (histone deacetylase 1), corresponding to Class II; and Sir2 (silent information regulator 2), corresponding to Class III [51] . HDACs are divided into the following classes: class I (HDAC1-3 and 8), class II (HDAC4-7, 9 and 10), class III (sirtiun1-7) and class IV (HDAC11).
HMTs are enzymes, HKMTs (histone-lysine N-methyltransferases) and HRMTs (histone-arginine N-methyltransferases), which catalyse the transfer of one to three methyl groups from the cofactor SAM to lysine and arginine residues of histone proteins. HKMT proteins often contain an SET [Su(var)3-9, Enhancer of Zeste, Trithorax] domain and they make up the SET-domain protein methyltransferase family. The exception to the rule is the DOT1 family, members of which methylate Lys 79 in the globular region of histone H3 and which are structurally not related to SET-domain proteins [52] . Protein arginine methylation, including of histones, is a covalent posttranslational modifi cation carried out by a family of enzymes, the PRMTs (protein arginine methyltransferases). PRMTs use SAM as a methyl donor and add one or two methyl groups onto the guanidino nitrogens of the arginine residue. In humans, the PRMT family consists of nine members [35] . In particular, histones are substrates of PRMT1, CARM1 (also referred to as PRMT4), and PRMT5, which can be therefore considered a HRMT [53] .
Histone methylation is now considered a more dynamic modifi cation with the discovery of HDMs. Levels of lysine methylation on histone tails are known to change during processes such as transcriptional regulation. Therefore it was proposed that specifi c enzymatic activity might remove the methyl groups [54] . Indeed, amine oxidation by LSD1 (lysine-specifi c demethylase 1) and hydroxylation by JmjC-domain-containing proteins (including the subfamily of proteins: JHDM1, PHF2/PHF8, JARID, JHMD3/JMJD2, UTX/UTY, JHDM2 and JmjC only) are histone-modifying enzymes that can remove methyl groups on lysine residues [55] . It was proposed that reversal of arginine methylation might be catalysed by deiminases. PADI4 is a nuclear member of the peptidyl arginine deiminase family which deiminate arginine residues on histones H3 and H4 by converting them into citrulline [39, 56, 57] .
Aberrant modifi cations of histones: hallmarks of cancer
Overall, post-translational modification of histones provide an epigenetic mechanism for the regulation of a variety of normal and disease-related processes. Thus, considering the fundamental roles of histone modifi cations, it is not surprising that aberrations in histone modifi cations are discovered in cancer. Aberrant modifi cations of histones associated with subtelomeric DNA and other DNA repeats have been reported. These aberrations include lower levels of histone H4K16ac, H4K20me3 and H3K27me3 [58] . Interestingly, loss of H4K16 acetylation and H4K20 trimethylation have been suggested to be common hallmarks of cancer cells [59] . The loss of these repressive marks leads to a more 'relaxed' chromatin conformation in these regions and might contribute to genome instability. Global enzymatic modifications of single residues on histone tails can be correlated with the state of stress within the cells with surprising accuracy [60] . Histone modifi cation patterns based on H3K4me2 and H3K18ac can predict the risk of tumour recurrence for prostate cancer.
Alterations in modifi cations of histones have also been linked to deregulated expression of many genes with important roles in cancer development and progression. Promoter CpG-island hypermethylation in cancer cells is known to be associated with a particular combination of histone marks: deacetylation of histones H3 and H4, loss of H3K4me3, and gain of H3K9me and H3K27me3 [61, 62] . It is also recognized that certain genes with tumoursuppressor-like properties, such as p21 WAF1 , are silent at the transcriptional level in the absence of CpG-island hypermethylation when hypoacetylated and hypermethylated histones H3 and H4 are present [63] .
In addition, growing evidence suggests that the different types of histonemodifying enzymes are found deregulated in human cancers. An extensive analysis of expression patterns of histone-modifying enzymes was able to discriminate tumour samples from their normal counterparts and cluster the tumour samples according to cell type [64] . Genes that encode HAT enzymes have been found to be translocated, amplifi ed, overexpressed or mutated in both solid tumours and haematological malignancies [65] . For example, HAT hMOF (GNAT-MYST family) is frequently down-regulated in primary breast carcinoma and medulloblastoma [66] . Leukaemias and uterine myomas carry translocations that generate fusion proteins such as CBP-MOZ and CBP-MORF that disrupt the acetylation of histone H4 [67, 68] . Altered expression and mutations of genes that encode HDACs have been linked to tumour development since they both induce the aberrant transcription of key genes regulating important cellular functions such as cell proliferation, cell-cycle regulation and apoptosis [69] . Overexpression of HDACs has also been reported in cancer. For example, there is an increase in HDAC1 expression in gastric, prostate, colon and breast carcinomas. Overexpression of HDAC2 has been found in cervical, gastric and colorectal carcinoma. Other studies have reported high levels of HDAC3 and HDAC6 expression in colon and breast cancer specimens respectively. SIRT1 levels are increased in a number of tumour cell types. Mutational inactivation of HDAC2 in human cancers has also reported to confer resistance to HDAC inhibition induced cell death.
Several HMTs have been linked to different types of cancer. Of the approx. 50 arginine and lysine HMTs encoded in the human genome, at least 22 have been associated with cancer or other diseases in humans or in mouse models, and misregulation of some HMTs has also been associated with cancer aggressiveness [70] . In parallel, numerous deregulations of HDM functions have also been recently reported in cancer. Both gain-and loss-of-function for HDMs are reported [71] .
The potential apoptotic histone code
Chromatin condensation paralleled by DNA fragmentation is one of the most important nuclear events occurring during apoptosis. DNA is associated with histone proteins; hence, hallmark properties of apoptosis, such as chromatin condensation, may be regulated by post-translational histone modifi cations. Indeed, histone modifications, and in particular phosphorylation and acetylation, have been suggested to affect chromatin function and structure during cell death. Histone phosphorylation at specific sites, in particular, has been shown to be involved in structural changes in chromatin during the cell cycle. The cdc2/H1 kinase-dependent phosphorylation of H1 histones during the cell cycle is a dynamic process with a phosphorylation maximum during mitosis [72] . During induction of apoptosis, but before initiation of nucleosomal fragmentation, H1 histones are rapidly dephosphorylated, a process which accompanies condensation of chromatin.
Aurora B kinase and MSK1/2 (mitogen-and stress-activated kinases 1/2) have been shown to be responsible for phosphorylation of Ser 10 and Ser 28 on histone H3 (H3-S10ph and H3-S28ph), phosphorylation events that mark the compaction of chromatin during mitosis [73] . It is worth noting that overexpression of Aurora B kinase promotes tumour cell proliferation and inhibits apoptosis, whereas inhibition of the kinase induces cell death [74] . MSK1/2 have also been reported to negatively regulate apoptosis [75] . In parallel, histone H2B phosphorylation at Ser 14 (H2B-S14ph) has been proposed as an epigenetic marker of apoptotic cells associated with DNA degradation [76, 77] , whereas acetylation at the adjacent Lys 15 (H2B-K15ac) is a property of non-dying cells. The modifi cation appeared to be reciprocal, and deacetylation of H2BK15 is necessary to allow H2BS14 phosphorylation. Phosphorylation of H2BS14 is catalysed by Mst1 (mammalian sterile twenty) kinase. Mst1 promotes H2BS14ph in vitro and in vivo, and the onset of H2BS14 phosphorylation is dependent upon cleavage and activation of Mst1 by caspase 3. RCC1 (regulator of chromosome condensation 1) reads the histone code created by caspase-activated Mst1 to initiate apoptosis by reducing the level of RanGTP in the nucleus, which leads to inactivation of the nuclear transport machinery. As a consequence, nuclear-localization-signal-containing proteins, including survival factors such as NF-κB-p65, remain bound to importins α and β in the cytoplasm. Apoptosis-induced acetylation on H2BK12 (H2B-K12ac) has also been reported [78] .
Histone H2A.X phosphorylation on Ser 139 (H2A-S139ph) in response to DNA damage is the major signal for the assembly of the so-called γ-H2AX chromatin domain, a region surrounding an unrepaired DNA double-strand break that is characterized by the accumulation of a large number of DNA-damage response proteins [79] . However, γ-H2AX, a hallmark of the DNA-damage response, also forms early during apoptosis induced by death receptor agonists (TRAIL and FasL) and staurosporine targeting the intrinsic apoptotic pathway [80] [81] [82] . The recent discovery of H2AX Tyr 142 phosphorylation (H2AX-Y142ph) by the WICH complex and its dephosphorylation by the EYA1/3 phosphatases may provide substantial novel insight into this process [83] . WSTF, a subunit of the WICH complex, bears a novel kinase domain at its N-terminus that constitutively targets H2AX-Y142ph. This novel histone modifi cation appears to determine the relative recruitment of either DNA repair or pro-apoptotic factors to sites of DNA damage and allows it to function as an active determinant of repair/ survival compared with apoptotic responses to DNA damage. Thus the balance of H2AX-Y142ph phosphorylation/dephosphorylation may constitute a novel switch mechanism to determine cell fate after DNA damage [84] . Collectively these data provide evidence for a potential apoptotic 'histone code'. These unique histone modifi cations occurring during the course of cell death provide new features to monitor and study apoptosis (Figure 2) .
Furthermore, covalent histone modifi cation has also been reported to regulate the expression of the cell-death-related gene. Epigenetic silencing in cancer cells is mediated by at least two distinct histone modifi cations, polycomb (EZH2)-based H3K27me3 and PcG (polycomb)-based H3K9me2 [85] . Promoters silenced by epigenetic mechanism include those for the apoptosisrelated gene p16 INK4a [86] , p57 Kip2 [87] , GAS2 and PIK3CG and p21 Waf [63] . miRNAs miRNAs: key regulators of gene expression miRNAs are small non-coding RNAs that regulate the expression of complementary mRNAs and function as key controllers in a myriad of cellular processes, including proliferation, differentiation and apoptosis. The miRNA biogenesis is an organized cellular process involving RNA-mediated gene silencing (Figure 3) . miRNA alteration in cancer miRNAs are considered as one of the most abundant classes of regulatory genes in humans. Curiously, more than half of all miRNA genes are located in cancer-associated genomic regions or fragile sites, which are frequently altered during cancer development. Large-scale profi ling of miRNAs has revealed that miRNA deregulation is a marker of cancers. In cancer, miRNA expression is highly specifi c for tissues and developmental stage [88] , and that has allowed for molecular classifi cation of tumors [89] , drawing attention to its potential in cancer diagnosis. For instance, miRNA miR-21 is up-regulated in a wide variety of cancers, both solid and haematological tumours. This miRNA has been shown to play a role as a marker of early detection of PDAC (pancreatic ductal adenocarcinoma). Besides miR-21, other miRs including miR-155, miR-181b, miR-221 and miR-222 are also frequently up-regulated in cancers of the blood, brain, thyroid and the GI (gastro-intestinal) systems, and to a lesser extent in liver cancer, lung cancer and breast cancer.
miRNAs regulating apoptosis as oncogenes and tumour suppressors
One of the most important links between miRNA function and cancer pathogenesis is supported by the alteration of pro-and anti-apoptotic genes. Down-regulated miRNAs in cancerous cells are considered as tumour suppressor genes. Tumour suppressor miRNAs usually prevent tumour development by negatively inhibiting oncogenes and/or genes that control cell differentiation or apoptosis. However, miRNA overexpressed in tumours In 'normal' non-dying cells, nucleosomes are enriched in histone-modifi cation marks, such as the Aurora B/MSK1/2-dependent phosphorylation of Ser 10 and Ser 28 on histone H3, and the acetylation of Lys 15 on histone H2B (H2B-K15ac) carried out by the HAT CBP/p300. In apoptotic cells, this scenario is disrupted by the loss of the H2B-K15ac marks, which allow the caspase 3-activated Mst1 kinase-dependent phosphorylation of Ser 14 on histone H2B. Acetylation of Lys 22 on histone H2B is also reported in apoptotic cells. DNA-PK-dependent-histone H2A phosphorylation on Ser 139 (known as γ-H2AX), a hallmark of the DNA-damage response, forms early during apoptosis at the nuclear periphery, forming the so-called 'γ-H2AX ring'. H2AX Tyr 142 phosphorylation by the WICH complex and its dephosphorylation by the EYA1/3 phosphatases appears to determine the relative recruitment of either DNA repair or pro-apoptotic factors to sites of DNA damage and allows it to function as an active determinant of repair/survival compared with apoptotic responses to DNA damage. Collectively these results provide evidence for a potential apoptotic 'histone code'. may be considered as oncogenes and usually promote tumour development by negatively inhibiting tumour suppressor genes and/or genes that control cell differentiation or apoptosis. In fact, the let-7 miRNA is generally expressed at low levels in cancerous lung tissue compared with normal tissue. Furthermore, the low expression of let-7 correlates inversely with the level of RAS oncogene proteins, but not RAS mRNA levels, suggesting that let-7 regulation of RAS is a mechanism for let-7 to function as a tumour suppressor gene in lung oncogenesis [90] . The miR-17-92 cluster is highly expressed in many tumours, including lung tumours. This cluster increases the expression of the oncogenic Figure 3 . miRNA biogenesis and therapeutic strategies in cancer (A) miRNA biogenesis is an organized process; primary transcripts RNAs (Pri-miRNA) are generated in the nucleus by polymerase II. The transcription product is capped at the 5´ end, polyadenylated to give a (poly)A tail and spliced to form Pri-miRNA. The processing of pri-miRNAs is mediated by DiGeorge Syndrome Critical Region 8 (DGCR8) protein, the cofactor to drosha. Together, drosha and DGCR8 form the microprocessor complex and cleave both strands of the hairpin stem, thus producing pre-miRNAs which are transported to the cytoplasm by the nuclear membrane protein exportin 5 using Ran-GTP. Once in the cytoplasm, pre-miRNAs encounter a second RNase II endonuclease, Dicer, which cleaves the double-stranded RNA from the end, subsequently releasing the mature miRNA. Dicer cleavage of pre-miRNA may generate an imperfect miRNA, leading to protein level decrease without a decrease in mRNA levels. This phenomenon is called translational repression. However, in the case of a perfect complementarity of miRNA with mRNA, miRNAs can act as small interfering RNAs (siRNAs), inducing mRNA degradation, indicating that siRNAs may also be able to function as miRNAs. (B) Several recent studies identifi ed specifi c miRNAs that are down-regulated in more than one major tumour cell line cluster; they also found that the re-expression of those miRNAs in many cancer cell lines effi ciently induce cell death. In miRNA re-expression therapeutic strategy, overexpressed specifi c pro-apoptotic miRNAs target the anti-apototic proteins and consequently induce apoptosis; similarly the re-expressed specifi c anti-apoptotic miRNAs induce pro-apoptotic proteins and as a result induce apoptosis. ORF, open reading frame.
c-Myc gene. Consequently c-Myc up-regulation induces down-regulation of the transcription factor E2F1 protein expression [91] . This level of E2F1 expression results in the inhibition of apoptosis through the ARF-p53 pathway, and causes cancer pathogenesis in several organs, including lung cancer and lymphomas. In this regulatory mechanism, miR-17-92 functions as an oncogene. miRNAs and apoptosis miRNAs can regulate more than one protein-coding gene in the human genome. Therefore, in cancer, several miRNAs have been shown to be implicated in regulating the expression of cell proliferation and apoptosis proteins. Some miRNAs are implicated only in apoptosis, whereas others may play roles in both the apoptotic and cell-proliferation pathways [88] .
The anti-apoptotic miRNAs
Individual miRNAs such as miR-21 have been found to regulate more than one phenoytype, including apoptosis and proliferation [92, 93] . MiR-21 knockdown in human glioblastoma cells has been shown to increase apoptosis through the caspase pathway. This miRNA inhibition highlighted its role as an antiapoptotic factor. Also in glioblastoma cells miR-21 is found to target directly PTEN (phosphatase and tensin homologue deleted on chromosome 10), reducing apoptosis [94] . In breast cancer, miR-21 regulates the proto-oncognes and tumour suppressor protein PDCD4 (programmed cell death 4) [95] . This tumour suppressor whose deregulation leads to tumorigenesis, regulates important cellular processes, including cell growth, proliferation and apoptosis. Additionally, miRNA-21 has been shown to acts as anti-apoptotic factor in regulating IL-6 and STAT3 (signal transducer and activator of transcription 3) [96] . STAT3 plays a central role in IL-6-mediated cell proliferation by inhibiting apoptosis.
Pro-apoptotic miRNAs
The miR-15-16 cluster induces apoptosis by targeting the anti-apoptotic Bcl-2 at the post-transcriptional level [97] . Bcl-2 repression by miR-15-16-clusterinduced apoptosis seems to be the main regulatory mechanism involved in the pathogenesis of leukaemic cell line model. In fact, the miRNAs miR-15-16 are located on human chromosome 13 in a region frequently deleted in B-CLL (B-cell chronic lymphocyte leukaemia) and its levels are inversely correlated with Bcl-2 protein levels in CLL patients. Down-regulation of miR-15-16 cluster was also reported in other human malignancies such as pituitary adenoma and prostate carcinoma. This cluster is considered a natural antisense of Bcl-2 inhibitor. Furthermore, overexpression of miR-15-16 in a leukaemic cell line results in decreased Bcl-2 protein expression, activation of the intrinsic apoptosis pathway and ultimately cell death. Another miRNA down-regulated is miR-29b, which is associated with lung and prostate cancers. MiR-29b has been also reported with target MCL1 (myeloid cell leukaemia sequence 1) (an anti-apoptotic member of the Bcl-2 family), implying that the function of miR-29b may be similar to that of miR-15-16. The miR-34 family has been identifi ed as components of tumour suppressor and pro-apoptotic miRNAs. Ectopic expression of miR-34 induces cell-cycle arrest in both primary and tumour-derived cell lines. He et al. [98] were the fi rst to identify that p53 can induce expression of miR-34. miR-34 inhibition of SIRT1 in colon cancer cells leads to an increase in acetylated p53 and expression of p21 and PUMA, transcriptional targets of p53 that regulate the cell cycle and apoptosis respectively. The perturbation of miR-34 expression as occurs in some human cancers, may thus contribute to tumorigenesis by attenuating p53-dependent apoptosis. Therefore a miR-34 re-expression may induce apoptosis in these cancers [99] .
To date, there are a total of 6396 miRs, of which, 678 miRs are found in humans [100] . However, mRNA targets and regulatory pathways have only been explored for a few miRNAs. The complexity of understanding miRNA regulation is due to the high number of target genes that can be regulated by one single miRNA (200 target genes according to bioinformatics analysis). Additionally, each cell type may be defi ned by a unique set of miRNAs that control gene expression.
epi-drugs induced cancer cell death
Since aberrant epigenetic changes are a hallmark of cancer, the reversible nature of epigenetic aberrations has led to the emergence of the promising fi eld of epigenetic therapy, which is already making progress, with the recent USA FDA (Food and Drug Administration) approval of three epigenetic drugs, known as epi-drugs, for cancer treatment. Epigenetic therapy of cancer is based mostly on the use of DNMT inhibitors, HDAC inhibitors and anti-miRNA therapy.
The expression and regulation of DNA methylation and the subsequent chromatin structure are signifi cantly altered in cancer cells, underlying the benefi ts of DNA demethylating agents, DNMT inhibitors, for cancer therapy. Treatment with DNMT inhibitors, such as the nucleoside analogue pan-dnmt inhibitor, 5-azaC (5-azacytidine), and its deoxy analogue, 5-azaCdR (5-deoxycytidine), a potent and non-selective DNA methylation inhibitor, lead to the reactivation of pro-apoptotic genes, and subsequent cell death in numerous tumour cell types [101] .
Since HDAC inhibition prompts tumour cells to enter apoptosis, small molecule HDAC inhibitors have been developed as a new class of anti-cancer agents, many of which have entered clinical trials. HDAC inhibitors are a structurally diverse group of molecules, or epi-drugs, which can induce cancer cell death, whereas normal cells are relatively resistant [102] . HDAC inhibitors may act through the reactivation of dormant tumour suppressor genes. They also modulate the expression of several genes related to apoptosis. Furthermore, as histone acetylation plays a role in the regulation of chromatin structure and gene expression, two determinant parameters of the DNAdamage response, HDAC inhibitors have been shown to enhance radio-and chemo-sensitivity of tumour cells [103, 104] . A synergistic effect of the combined use of DNMT and HDAC inhibitors has been observed [105] . HDAC inhibitors, in combination with DNA-demethylating agents, chemopreventive, or classical chemotherapeutic drugs, could be promising candidates for cancer therapy. Actually, in 2006 Vorinostat [SAHA (suberoylanilide hydroxamic acid)] was the fi rst epi-drug approved by FDA for the treatment of cutaneous T-cell haematological malignancies [106] . Novel polyamine analogues have been shown to be potent inhibitors of the HDM LSD1, promote histone methylation and represent a highly promising addition to the armamentarium of epi-drugs to modulate cancer cell death [107] .
Finally, every cellular process, including cell death, is likely to be regulated by miRNAs, and an aberrant expression signature of these small non-coding RNAs is a hallmark of several diseases, including cancer [108] . It has been shown that miRNAs can function as potential oncogenes or tumour suppressor genes, depending on the cellular context and on the target genes they regulate. Thus the possibility of modulating miRNA expression by developing synthetic pre-miRNA molecules or antisense oligonucleotides have at the same time provided a powerful tool to develop a deeper comprehension of the molecular mechanisms regulated by these molecules, and suggested the intriguing and promising perspective of their possible use in therapy [109] .
Conclusion
During recent years, epigenetic alterations in the cell-death pathways and their implication in cancer have received increasing attention. Consequently, the list of enzymes involved in the epigenome is steadily increasing. In parallel, the list of genes subject to abnormal epigenetic expression regulation is also rapidly growing. However, in most cases, our comprehension of the molecular mechanism that contributes to cancer development or progression is still quite limited. In addition, even if changes in the epigenetic landscape can be considered as a hallmark of cancer, epigenetic diversity is also a characteristic of cancer, and should be considered, if not cell-specifi c, at least as tumourtype-specifi c. Further understanding of the different signalling pathways that control apoptosis in the different tumour types and their epigenetic regulation, will help with the discovery of novel targeted agents and the design of clinical trials that are based on the molecular defects specifi c to the targeted tumour. Most encouragingly, research in epigenetics has led to improved survival of patients with certain forms of lymphoma and leukaemias through the use of drugs that alter DNA methylation and histone acetylation. In addition, there are numerous other clinical applications of the fi eld being explored in areas such as cancer screening and early detection, prevention, classifi cation for epidemiology and prognostic purposes, and predicting outcomes after standard therapy. In conclusion, despite the complexity and heterogeneity of cancer, the fi eld of epigenetic therapy, especially with the development of novel epi-drugs (HDAC and HDM inhibitors) and miRNA-based therapy which reactivates the cell death programme, provides, alone or in combination with current therapeutic modalities, possibilities for treating human cancers. 
Summary

